These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28073004)

  • 1. Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
    Veschi V; Liu Z; Voss TC; Ozbun L; Gryder B; Yan C; Hu Y; Ma A; Jin J; Mazur SJ; Lam N; Souza BK; Giannini G; Hager GL; Arrowsmith CH; Khan J; Appella E; Thiele CJ
    Cancer Cell; 2017 Jan; 31(1):50-63. PubMed ID: 28073004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
    Wada M; Kukita A; Sone K; Hamamoto R; Kaneko S; Komatsu M; Takahashi Y; Inoue F; Kojima M; Honjoh H; Taguchi A; Kashiyama T; Miyamoto Y; Tanikawa M; Tsuruga T; Mori-Uchino M; Wada-Hiraike O; Osuga Y; Fujii T
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
    Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
    Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PPARγ-SETD8 axis constitutes an epigenetic, p53-independent checkpoint on p21-mediated cellular senescence.
    Shih CT; Chang YF; Chen YT; Ma CP; Chen HW; Yang CC; Lu JC; Tsai YS; Chen HC; Tan BC
    Aging Cell; 2017 Aug; 16(4):797-813. PubMed ID: 28514051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma.
    Herviou L; Ovejero S; Izard F; Karmous-Gadacha O; Gourzones C; Bellanger C; De Smedt E; Ma A; Vincent L; Cartron G; Jin J; De Bruyne E; Grimaud C; Julien E; Moreaux J
    Clin Epigenetics; 2021 Sep; 13(1):174. PubMed ID: 34530900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
    Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
    Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Determinants of Erythropoiesis: Role of the Histone Methyltransferase SetD8 in Promoting Erythroid Cell Maturation and Survival.
    DeVilbiss AW; Sanalkumar R; Hall BD; Katsumura KR; de Andrade IF; Bresnick EH
    Mol Cell Biol; 2015 Jun; 35(12):2073-87. PubMed ID: 25855754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted inhibition of the methyltransferase SETD8 synergizes with the Wee1 inhibitor adavosertib in restraining glioblastoma growth.
    Della Monica R; Buonaiuto M; Cuomo M; Pagano C; Trio F; Costabile D; de Riso G; Cicala FS; Raia M; Franca RA; Del Basso De Caro M; Sorrentino D; Navarra G; Coppola L; Tripodi L; Pastore L; Hench J; Frank S; Schonauer C; Catapano G; Bifulco M; Chiariotti L; Visconti R
    Cell Death Dis; 2023 Sep; 14(9):638. PubMed ID: 37758718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors.
    Milite C; Feoli A; Viviano M; Rescigno D; Mai A; Castellano S; Sbardella G
    ChemMedChem; 2016 Aug; 11(16):1680-5. PubMed ID: 27411844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells.
    Kukita A; Sone K; Kaneko S; Kawakami E; Oki S; Kojima M; Wada M; Toyohara Y; Takahashi Y; Inoue F; Tanimoto S; Taguchi A; Fukuda T; Miyamoto Y; Tanikawa M; Mori-Uchino M; Tsuruga T; Iriyama T; Matsumoto Y; Nagasaka K; Wada-Hiraike O; Oda K; Hamamoto R; Osuga Y
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
    Ma A; Yu W; Li F; Bleich RM; Herold JM; Butler KV; Norris JL; Korboukh V; Tripathy A; Janzen WP; Arrowsmith CH; Frye SV; Vedadi M; Brown PJ; Jin J
    J Med Chem; 2014 Aug; 57(15):6822-33. PubMed ID: 25032507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone methyltransferase Setd8 acts in concert with c-Myc and is required to maintain skin.
    Driskell I; Oda H; Blanco S; Nascimento E; Humphreys P; Frye M
    EMBO J; 2012 Feb; 31(3):616-29. PubMed ID: 22117221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone methyltransferase Setd8 represses Gata2 expression and regulates erythroid maturation.
    Malik J; Getman M; Steiner LA
    Mol Cell Biol; 2015 Jun; 35(12):2059-72. PubMed ID: 25848090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC.
    Li X; Liu Z; Xia C; Yan K; Fang Z; Fan Y
    Cancer Lett; 2022 Feb; 527():150-163. PubMed ID: 34942305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological and transcriptional inhibition of the G9a histone methyltransferase suppresses proliferation and modulates redox homeostasis in human microvascular endothelial cells.
    Wojtala M; Macierzyńska-Piotrowska E; Rybaczek D; Pirola L; Balcerczyk A
    Pharmacol Res; 2018 Feb; 128():252-263. PubMed ID: 29113759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone methyltransferase Setd8 alters the chromatin landscape and regulates the expression of key transcription factors during erythroid differentiation.
    Myers JA; Couch T; Murphy Z; Malik J; Getman M; Steiner LA
    Epigenetics Chromatin; 2020 Mar; 13(1):16. PubMed ID: 32178723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Chromatin-Focused siRNA Screen for Regulators of p53-Dependent Transcription.
    Sammons MA; Zhu J; Berger SL
    G3 (Bethesda); 2016 Aug; 6(8):2671-8. PubMed ID: 27334938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.
    Schwermer M; Lee S; Köster J; van Maerken T; Stephan H; Eggert A; Morik K; Schulte JH; Schramm A
    Oncotarget; 2015 Jun; 6(17):15425-35. PubMed ID: 26029996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.